Lebenthal Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Lebenthal Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,975	Closed	-$137K	–	641
2016 Q3	$137K	Buy	+2,975	New	+$155K	0.02%	318

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Lebenthal Asset Management's TEVA Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2016, closing a stake of 2,975 shares — an estimated $137K sold.

Lebenthal Asset Management first reported a position in TEVA in Q3 2016 and held it in 1 quarter. The position peaked at $137K in Q3 2016. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Lebenthal Asset Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2016 after selling out during the quarter.
Lebenthal Asset Management sold 2,975 Teva Pharmaceutical Industries Limited shares in Q4 2016, an estimated $137K.
Lebenthal Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2016 and held it in 1 quarter.
Lebenthal Asset Management's Teva Pharmaceutical Industries Limited position peaked at $137K in Q3 2016.
739 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.